16498 Federal Register / Vol. 87, No. 56 / Wednesday, March 23, 2022 / Notices 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment.’’ 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on January 17, 2022, 

Siemens Healthcare Diagnostics Inc., 

100 GBC Drive, Mailstop 514, Newark, 

Delaware 19702–2461, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Ecgonine ......................... 9180 II 

The company plans to produce the 

listed controlled substance in bulk to be 

used in the manufacture of DEA exempt 

products. No other activities for these 

drug codes are authorized for this 

registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06162 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–986] 

Bulk Manufacturer of Controlled 

Substances Application: Usona 

Institute, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Usona Institute, Inc. has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before May 23, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 23, 2022. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on February 16, 2022, 

Usona Institute, Inc., 2780 Woods 

Hollow Road, Room 2413, Fitchburg, 

Wisconsin 53711, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Psilocybin ..................... 7437 I 

Psilocin ......................... 7438 I 

The company plans to bulk 

manufacture the listed controlled 

substances for use in chemical process 

development as well as pre-clinical and 

clinical research. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06166 Filed 3–22–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–987] 

Bulk Manufacturer of Controlled 

Substances Application: Patheon API 

Manufacturing, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Patheon API Manufacturing, 

Inc. has applied to be registered as a 

bulk manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplementary Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before May 23, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

May 23, 2022. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on March 2, 2022, Patheon 

API Manufacturing, Inc., 309 Delaware 

Street, Greenville, South Carolina 

29605–5420, applied to be registered as 

a bulk manufacturer of the following 

basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric 

Acid.

2010 I 

Tetrahydrocannabinols 7370 I 

5-Methoxy-N-NDimethyltryptamine.7431 I 

Alpha-Methyltryptamine 7432 I 

Dimethyltryptamine ....... 7435 I 

Psilocybin ..................... 7437 I 

Psilocyn ........................ 7438 I 

Thebaine ....................... 9333 II 

Oxymorphone ............... 9652 II 

Noroxymorphone .......... 9668 II 

The company plans to bulk 

manufacture the listed controlled 

substances as an Active Pharmaceutical 

Ingredient (API) for distribution to its 

customers. In reference to dug code 

7370 (Tetrahydrocannabinols), the 

company plans to bulk manufacture this 

drug as synthetic. No other activities for 

these drug codes are authorized for this 

registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–06167 Filed 3–22–22; 8:45 am] 

BILLING CODE P 


jspears on DSK121TN23PROD with NOTICES1